lopinavir/ritonavir, Drugs Monitor, Page 2

(11 Aug 2020) Hydroxychloroquine, Lopinavir/R- No statistically significant differences with HCQ or LPV/RTV

August 20, 2020

Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort https://doi.org/10.1007/s00508-020-01720-y Of 156 patients (41% female) with a median age of 72 years (IQR 55.25-81) admitted to our department, 67 patients fulfilled the inclusion criteria (20… Continue reading "(11 Aug 2020) Hydroxychloroquine, Lopinavir/R- No statistically significant differences with HCQ or LPV/RTV"

(03 Aug 2020) Lopinavir/R & Chloroquine- did not improve the prognosis or shorten the clinical course of COVID-19

August 4, 2020

A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients https://doi.org/10.1097/QAI.0000000000002452 A retrospective study to summarize the clinical practices of non-severe patients with COVID-19 receiving the standard care, LPV/r or chloroquine was conducted. Of the… Continue reading "(03 Aug 2020) Lopinavir/R & Chloroquine- did not improve the prognosis or shorten the clinical course of COVID-19"

(01 Aug 2020) Lopinavir/Ritonavir- a high frequency of DDI between LPV-r for treating COVID-19

August 4, 2020

High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment https://doi.org/10.1101/2020.07.30.20165027 Overall, 469 patients were diagnosed of COVID-19, 125 (27%) of them were prescribed LPV-r. LPV-r had potential DDI with concomitant medications in 97 (78%, 95% CI: 69%-85%) patients,… Continue reading "(01 Aug 2020) Lopinavir/Ritonavir- a high frequency of DDI between LPV-r for treating COVID-19"

(13 July 2020) Hydroxychloroquine, lopinavir/Ritonavir- no difference was found between HCQ or LPV/r as compared to standard of care

July 14, 2020

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis https://doi.org/10.1186/s13054-020-03117-9 In this retrospective observational study, eighty patients were treated during a 4-week period and included in the analysis: 22 (28%)… Continue reading "(13 July 2020) Hydroxychloroquine, lopinavir/Ritonavir- no difference was found between HCQ or LPV/r as compared to standard of care"

(05 July 2020) Lopinavir/Ritonavir- associated with faster pneumonia resolution within two weeks after symptom onset (37% vs 1%, P=0.001)

July 7, 2020

Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study https://doi.org/10.1002/jmv.26260 This is a retrospective study of 128 hospitalized patients with COVID-19 pneumonia. All patients were positive severe acute respiratory syndrome coronavirus 2… Continue reading "(05 July 2020) Lopinavir/Ritonavir- associated with faster pneumonia resolution within two weeks after symptom onset (37% vs 1%, P=0.001)"

(21 May 2020) Lopinavir/Ritonavir- Earlier administration of LPV/r treatment could shorten viral shedding duration

May 22, 2020

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection https://erj.ersjournals.com/content/early/2020/05/13/13993003.00799-2020 In a retrospective study of the 120 patients, 78 patients (65%) were administered with LPV/r treatment. The median duration of… Continue reading "(21 May 2020) Lopinavir/Ritonavir- Earlier administration of LPV/r treatment could shorten viral shedding duration"

(19 May 2020) Lopinavir/Ritonavir- higher concentrations are required to reach the assumed EC50

May 20, 2020

Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) https://www.acpjournals.org/doi/10.7326/M20-1550 This reports the first pharmacokinetic data of lopinavir and ritonavir in patients hospitalized with COVID-19. Lopinavir trough levels were approximately 2-fold higher in COVID population than… Continue reading "(19 May 2020) Lopinavir/Ritonavir- higher concentrations are required to reach the assumed EC50"

(16 May 2020) Arbidol-favorable clinical response when arbidol is combined with LPV/r

May 16, 2020

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. https://doi.org/10.1016/j.jinf.2020.03.002 In this retrospective cohort study, 16 patients received oral arbidol and LPV/r in the combination group and 17 received oral LPV/r only in… Continue reading "(16 May 2020) Arbidol-favorable clinical response when arbidol is combined with LPV/r"

(11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good

May 12, 2020

Observation of the efficacy and safety of lopinavir / ritonavir and abidor in the treatment of new coronavirus pneumonia http://rs.yiigle.com/yufabiao/1193931.htm This paper describes retrospective analysis of the clinical data of 178 patients diagnosed as COVID-19 , and divided into 59… Continue reading "(11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good"

(07 May 2020) Lopinavir/Ritonavir- no benefit was observed with lopinavir–ritonavir treatment beyond standard care

May 7, 2020

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus In a randomized, controlled, open-label trial of 199 patients with laboratory-confirmed SARS-CoV-2 infection; 99 were assigned to the lopinavir–ritonavir group, and 100 to the standard-care group. Treatment with lopinavir–ritonavir… Continue reading "(07 May 2020) Lopinavir/Ritonavir- no benefit was observed with lopinavir–ritonavir treatment beyond standard care"

Tag: lopinavir/ritonavir